by Janneke de Haan | Aug 21, 2024 | News, Publications
Interview lygature: progress on data storage and analysis enablement interview Introduction In our latest interview, we had the opportunity to speak with Jan-Willem Boiten, the leader of Work Package 2 (WP2) in the Immune-Image project. Jan-Willem shared exciting...
by Janneke de Haan | Jun 20, 2024 | News, Publications
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities PAPER Introduction Immunotherapy targeted to immune checkpoint inhibitors, such as the program cell death receptor (PD-1) and its ligand (PD-L1), has revolutionized cancer...
by Anne-Fleur | Jun 14, 2024 | News, Publications
Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease ABSTRACT Objective Improving patient selection and development of biological therapies such as vedolizumab in IBD requires a thorough understanding...
by Daisy van Schaijik | May 8, 2024 | News, Publications
Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET Abstract Background Distribution of mAbs into tumour tissue may occur via different processes contributing differently to the 89Zr-mAb...
by Daisy van Schaijik | May 8, 2024 | News, Publications
89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs Introduction 89Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies ([89Zr]Zr-mAbs)) can be used to study the biodistribution of...
by Anne-Fleur | Mar 26, 2024 | News, Publications
How to obtain the image‑derived blood concentration from 89Zr‑immuno‑PET scans ABSTRACT Background PET scans using zirconium-89 labelled monoclonal antibodies (89Zr-mAbs), known as 89Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is...
Recent Comments